MI&T Congressi
MI&T Srl has consolidated over ten years of proven experience in the organization of congresses, conferences and medical-scientific courses and in the provision of specific services for medical-scientific associations, in Italy and abroad.
3rd International Summit on Lung Cancer
MI&T Congressi
Potential Role of ADC in Early Stage NSCLC
FEATURING
Enriqueta Felip
- 31 views
- September 3, 2024
MI&T Congressi
Adaptive Mechanisms of Resistance to G12C(OFF) Inhibitors in NSCLC
FEATURING
Chiara Ambrogio
- 27 views
- September 3, 2024
MI&T Congressi
New Drugs for HER2 Deregulated NSCLC
FEATURING
Egbert Smit
- 51 views
- September 3, 2024
MI&T Congressi
Options for Osimertinib-Resistant NSCLC
FEATURING
Trever Bivona
- 167 views
- September 3, 2024
- 3
MI&T Congressi
Pharmacology of ADC Classes in Lung Cancer
FEATURING
Marzia Del Re
- 89 views
- August 27, 2024
MI&T Congressi
Tumor Immune Microenvironment and Immunotherapy Resistance
FEATURING
Dario Sangiolo
- 51 views
- August 27, 2024
- 1
MI&T Congressi
Potential Mechanisms of Resistance to ADCs
FEATURING
Jair Bar
- 39 views
- August 27, 2024
- 1
MI&T Congressi
Optimal Duration of Immunotherapy in NSCLC
FEATURING
Giulia Pasello
- 95 views
- August 20, 2024
- 1
MI&T Congressi
The Role of IO for Oncogene-Addicted NSCLC
FEATURING
Francesco Passiglia
- 54 views
- August 20, 2024
- 1
MI&T Congressi
New Drugs as Maintenance Therapy After CRT in Stage III NSCLC
FEATURING
Fabrice Barlesi
- 111 views
- August 20, 2024
- 1
MI&T Congressi
Neoadjuvant Chemoimmunotherapy in Unresectable NSCLC
FEATURING
Isabelle Opitz
- 152 views
- August 20, 2024
- 2
MI&T Congressi
How the Experts Manage: ADC-Associated Toxicities in NSCLC
FEATURING
Natasha Leighl
- 175 views
- August 8, 2024
MI&T Congressi
Anti-ALK NSCLC Agents as Adjuvant Therapy
FEATURING
Marina Chiara Garassino
- 80 views
- August 8, 2024
MI&T Congressi
Anti-EGFR Agents in the Adjuvant NSCLC Setting
FEATURING
Yi-Long Wu
- 25 views
- August 2, 2024
MI&T Congressi
MRD in Early Stage Oncogene-Addicted NSCLC
FEATURING
Nicola Normanno
- 47 views
- August 2, 2024
MI&T Congressi
How the Experts Manage: Cardiotoxicity and IO in NSCLC
FEATURING
Jordi Remon Masip
- 112 views
- August 2, 2024
MI&T Congressi
How to Select EGFR-Mutated Patients for EGFR+CT Combo in NSCLC
FEATURING
Pasi Janne
- 111 views
- July 26, 2024
- 2
MI&T Congressi
ADC in Combination With Immunotherapy for NSCLC
FEATURING
Stephen Liu
- 217 views
- July 26, 2024
- 1
MI&T Congressi
IO Long-Term Survival in Advanced NSCLC
FEATURING
Rolf A. Stahel
- 55 views
- July 25, 2024
MI&T Congressi
Selecting Patients for CTLA4 Therapy for NSCLC
FEATURING
Rafal Dziadziuszko
- 40 views
- July 25, 2024
MI&T Congressi
New Immune Checkpoint Inhibitors in Lung Cancer
FEATURING
Solange Peters
- 202 views
- July 25, 2024
- 1
MI&T Congressi
How the Experts Treat: Neoadjuvant Immunotherapy for Resected NSCLC
FEATURING
Mariano Provencio Pulla
- 86 views
- July 24, 2024
- 1
MI&T Congressi
How the Experts Treat: Adjuvant or Neoadjuvant Immunotherapy for NSCLC
FEATURING
Tina Cascone
- 144 views
- July 24, 2024
- 2
MI&T Congressi
N2 Disease in NSCLC: Who Is Resectable?
FEATURING
Mariana Brandão
- 127 views
- July 24, 2024
- 3
MI&T Congressi
Maintenance IO in Stage III Unresectable NSCLC
FEATURING
Anne-Marie Dingemans
- 35 views
- July 22, 2024
MI&T Congressi
Mediastinal Staging of Lung Cancer
FEATURING
Rocco Trisolini
- 491 views
- July 22, 2024
- 4
MI&T Congressi
Neoadjuvant and Adjuvant Therapies in NSCLC: Are We Saving Lives?
FEATURING
Giorgio Scagliotti
- 183 views
- July 22, 2024
- 4
MI&T Congressi
MET Exon 14 Skipping Mutations in NSCLC
FEATURING
Oliver Gautschi
- 191 views
- July 19, 2024
- 1
MI&T Congressi
Current and Future Options for Relapsed SCLC
FEATURING
Luis Paz-Ares
- 177 views
- July 18, 2024
- 1
MI&T Congressi
Immunotherapy for Patients With Mesothelioma
FEATURING
Joachim Aerts
- 61 views
- July 18, 2024
MI&T Congressi
How the Experts Treat: Adjuvant Immunotherapy for Resected NSCLC
FEATURING
Dolores Isla
- 88 views
- July 18, 2024
- 2
MI&T Congressi
Perspectives for NSCLC Patients Not Obtaining Complete Pathological Response
FEATURING
Tony Mok
- 62 views
- July 18, 2024
MI&T Congressi
Current ADC Development in NSCLC
FEATURING
Hossein Borghaei
- 185 views
- July 18, 2024
- 2
MI&T Congressi
Options for BRAF-Mutated NSCLC Patients
FEATURING
David Planchard
- 126 views
- July 16, 2024
MI&T Congressi
Preventing Lung Cancer: Hope or Reality?
FEATURING
Ugo Pastorino
- 58 views
- July 12, 2024
- 1
MI&T Congressi
How the Experts Treat: Neoadjuvant or Adjuvant Targeted Therapy in Resectable Oncogene-Addicted NSCLC
FEATURING
Jarushka Naidoo
- 161 views
- July 12, 2024
- 2
MI&T Congressi
Surgery at the Time of Immunotherapy for Early Stage NSCLC
FEATURING
Jonathan Spicer
- 58 views
- July 12, 2024
MI&T Congressi
Radiotherapy for N2 Resected NSCLC
FEATURING
Cécile Le Péchoux
- 29 views
- July 12, 2024